Compare KraneShares CSI China Internet ETF (KWEB) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs Mesoblast Limited — how do they compare? KraneShares CSI China Internet ETF trades at $27.49, while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: Mesoblast Limited is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| KWEB | MESO | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $42.94 | $20.96 |
52-Week Low | $23.63 | $12.88 |
Market Cap | — | $2.21B |
Enterprise Value | — | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB trades at $27.54, down 5.43% over 24 hours amid pressure on Chinese equities, with technical indicators showing a bullish moving average signal but neutral oscillators. Recent news highlights institutional buying and China's export strength, though regulatory and economic risks persist. The ETF focuses on Chinese internet and AI companies, with current sentiment mixed due to geopolitical and market volatility.
The outlook for KWEB hinges on China's economic recovery and AI sector growth, offering exposure to undervalued tech giants. Key risks include U.S.-China tensions and domestic regulatory shifts, while institutional accumulation suggests long-term confidence. Investors should weigh high growth potential against elevated geopolitical and market risks.
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
